SCHEMBL23143766

SCHEMBL23143766

COC(=O)CCSc1ccnc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.37
▸ PRNP P04156 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ GSTP1 P09211 1/20 0.35
▸ GSTM2 P28161 1/20 0.35
▸ CXCR1 P25024 1/20 0.34
▸ CXCR2 P25025 1/20 0.34
▸ ATR Q13535 1/20 0.34
▸ PTGS1 P23219 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ ABL1 P00519 1/20 0.31
▸ RIN1 Q13671 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22303458 0.83 KMT2A (0.42) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL21154735 0.81 CYP3A4 (0.41) ALDH1A1TDP1HSD17B10
SCHEMBL19785098 0.78 KMT2A (0.43) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL29506060 0.77 KMT2A (0.45) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL18319841 0.77 KMT2A (0.45) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL18320486 0.76 KMT2A (0.44) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL29603922 0.76 KMT2A (0.44) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL18320494 0.75 KMT2A (0.43) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL30660933 0.75 KMT2A (0.43) KMT2APRNPPOLBRXFP1GSTP1
SCHEMBL19785096 0.74 KMT2A (0.43) KMT2APRNPPOLBRXFP1GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230010886-A1 SHP2 INHIBITORS AND USES THEREOF Suzhou Puhe BioPharma Co., Ltd. (CN) 2023-01-12 — — US disclosed
US-20230010886-A1 SHP2 INHIBITORS AND USES THEREOF Suzhou Puhe BioPharma Co., Ltd. (CN) 2023-01-12 — — US disclosed
CN-114502165-A SHP2 inhibitor and application thereof 苏州浦合医药科技有限公司 2022-05-13 — — CN disclosed
WO-2021061515-A1 SHP2 INHIBITORS AND USES THEREOF SYNBLIA THERAPEUTICS, INC. (US) 2021-04-01 — — WO disclosed
WO-2021061515-A1 SHP2 INHIBITORS AND USES THEREOF SYNBLIA THERAPEUTICS, INC. (US) 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230010886-A1 SHP2 INHIBITORS AND USES THEREOF PTPN1, PTPN7, PTPN18 KMT2A 2029/4885PRNP 4573/4885POLB 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback